Cargando…

European principles of inhibitor management in patients with haemophilia

BACKGROUND: In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of many of these patients remains suboptimal and highly heterogenous across Europe. METHODS: Following a series of multidisciplinary me...

Descripción completa

Detalles Bibliográficos
Autores principales: Giangrande, P. L. F., Hermans, C., O’Mahony, B., de Kleijn, P., Bedford, M., Batorova, A., Blatný, J., Jansone, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921290/
https://www.ncbi.nlm.nih.gov/pubmed/29703220
http://dx.doi.org/10.1186/s13023-018-0800-z
_version_ 1783317976821268480
author Giangrande, P. L. F.
Hermans, C.
O’Mahony, B.
de Kleijn, P.
Bedford, M.
Batorova, A.
Blatný, J.
Jansone, K.
author_facet Giangrande, P. L. F.
Hermans, C.
O’Mahony, B.
de Kleijn, P.
Bedford, M.
Batorova, A.
Blatný, J.
Jansone, K.
author_sort Giangrande, P. L. F.
collection PubMed
description BACKGROUND: In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of many of these patients remains suboptimal and highly heterogenous across Europe. METHODS: Following a series of multidisciplinary meetings and a review of the literature, the European haemophilia community of health professionals and patients jointly defined practical optimum standards for ensuring and harmonizing treatment and care for patients with an inhibitor. RESULTS: Ten complementary principles for the management of inhibitors in haemophilia have been developed, emphasizing the importance and benefits of a centralized, multidisciplinary, expert and holistic approach. CONCLUSIONS: This document will serve as a benchmark to improve the multidisciplinary and practical management of patients with inhibitor. Implementation and adherence to each of these principles should have a major positive impact on the management and outcomes of patients developing an inhibitor.
format Online
Article
Text
id pubmed-5921290
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59212902018-05-01 European principles of inhibitor management in patients with haemophilia Giangrande, P. L. F. Hermans, C. O’Mahony, B. de Kleijn, P. Bedford, M. Batorova, A. Blatný, J. Jansone, K. Orphanet J Rare Dis Position Statement BACKGROUND: In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of many of these patients remains suboptimal and highly heterogenous across Europe. METHODS: Following a series of multidisciplinary meetings and a review of the literature, the European haemophilia community of health professionals and patients jointly defined practical optimum standards for ensuring and harmonizing treatment and care for patients with an inhibitor. RESULTS: Ten complementary principles for the management of inhibitors in haemophilia have been developed, emphasizing the importance and benefits of a centralized, multidisciplinary, expert and holistic approach. CONCLUSIONS: This document will serve as a benchmark to improve the multidisciplinary and practical management of patients with inhibitor. Implementation and adherence to each of these principles should have a major positive impact on the management and outcomes of patients developing an inhibitor. BioMed Central 2018-04-27 /pmc/articles/PMC5921290/ /pubmed/29703220 http://dx.doi.org/10.1186/s13023-018-0800-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Position Statement
Giangrande, P. L. F.
Hermans, C.
O’Mahony, B.
de Kleijn, P.
Bedford, M.
Batorova, A.
Blatný, J.
Jansone, K.
European principles of inhibitor management in patients with haemophilia
title European principles of inhibitor management in patients with haemophilia
title_full European principles of inhibitor management in patients with haemophilia
title_fullStr European principles of inhibitor management in patients with haemophilia
title_full_unstemmed European principles of inhibitor management in patients with haemophilia
title_short European principles of inhibitor management in patients with haemophilia
title_sort european principles of inhibitor management in patients with haemophilia
topic Position Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921290/
https://www.ncbi.nlm.nih.gov/pubmed/29703220
http://dx.doi.org/10.1186/s13023-018-0800-z
work_keys_str_mv AT giangrandeplf europeanprinciplesofinhibitormanagementinpatientswithhaemophilia
AT hermansc europeanprinciplesofinhibitormanagementinpatientswithhaemophilia
AT omahonyb europeanprinciplesofinhibitormanagementinpatientswithhaemophilia
AT dekleijnp europeanprinciplesofinhibitormanagementinpatientswithhaemophilia
AT bedfordm europeanprinciplesofinhibitormanagementinpatientswithhaemophilia
AT batorovaa europeanprinciplesofinhibitormanagementinpatientswithhaemophilia
AT blatnyj europeanprinciplesofinhibitormanagementinpatientswithhaemophilia
AT jansonek europeanprinciplesofinhibitormanagementinpatientswithhaemophilia
AT europeanprinciplesofinhibitormanagementinpatientswithhaemophilia